Cytodyn Inc (CYDY)

[z_smith]

Yes.

I can't help but to hark back to the comparison to TaiMed. TM has a substantially inferior monoclonal antibody product for treatment in COMBO HIV, yet when they hit their primary endpoint, they had a market cap of US$1.7B (or 14.5x our market cap). The only difference with us is that we have a weak balance sheet and no licensing deal yet.

(In fact, a couple of years ago there was a lively debate as to which company would bring their product to market first.)

The only reasonable explanation to the extreme discount we face is the market gives no credibility to CYDY. Hopefully, filing the BLA and signing the licensing deal will change that and we can start to gap up to a reasonable valuation.

Personally, I blame management for the weak balance sheet and for raising money at 1/14.5 what we should reasonably have been raising money at over the past years. There is unequivocal proof that a different management team with an inferior product, with far fewer indications, could do it. So, certainly CYDY could have done it as well.